Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 7/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356793 | 0.86 | ABCB1 (0.43) | ABCB1HTR1ATAS1R3TAS1R1HSD11B1 | |
| SCHEMBL17356807 | 0.85 | HTR1A (0.40) | ABCB1HTR1AHPGDTAS1R3TAS1R1 | |
| SCHEMBL17356810 | 0.79 | ADRA1A (0.42) | ABCB1HTR1ADRD2 | |
| SCHEMBL17356785 | 0.78 | HTR1A (0.38) | ABCB1HTR1ADRD2HCRTR1HCRTR2 | |
| SCHEMBL17356787 | 0.78 | HTR2C (0.40) | HPGDHSD11B1 | |
| SCHEMBL16955777 | 0.75 | ABCB1 (0.53) | ABCB1HTR1AHPGDDRD2HCRTR1 | |
| SCHEMBL10123010 | 0.75 | HTR2C (0.49) | TAS1R3TAS1R1HSD11B1DRD2 | |
| SCHEMBL17356792 | 0.75 | HTR2C (0.49) | TAS1R3TAS1R1HSD11B1DRD2 | |
| SCHEMBL17356789 | 0.73 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL27881934 | 0.73 | ALDH1A1 (0.43) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313792-A1 | METHOD FOR PRODUCING POLAR GROUP-CONTAINING OLEFIN POLYMER | THE UNIVERSITY OF TOKYO (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9499644-B2 | Production method of polar group-containing olefin polymers | SHOWA DENKO K.K. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150368376-A1 | PRODUCTION METHOD OF POLAR GROUP-CONTAINING OLEFIN POLYMERS | SHOWA DENKO K.K. (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368376-A1 | PRODUCTION METHOD OF POLAR GROUP-CONTAINING OLEFIN POLYMERS | OR10J3, OPRM1, ORC3 | ABCB1 3562/4885HTR1A 3188/4885HPGD 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.